Temozolomide for the treatment of metastatic melanoma: a systematic review.
about
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsTreatment of metastatic melanoma: an overviewTherapy for unresectable recurrent and in-transit extremity melanoma.A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumoursA phase I study of bortezomib and temozolomide in patients with advanced solid tumors.Malignant melanoma (metastatic)Angiogenesis and progression in human melanoma.Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanomaHistone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatmentIGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomidePhase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanomaPreclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesLow-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.Reactive oxygen species: an Achilles' heel of melanoma?Metastatic melanoma - a review of current and future drugsIn vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.Velimogene aliplasmid.Treatment of pituitary neoplasms with temozolomide: a review.Temozolomide in aggressive pituitary adenomas and carcinomas.Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas.Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis.Temozolomide (Temodar).Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.Expression of O⁶-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors.A microfluidic platform for drug screening in a 3D cancer microenvironment.Synthesis of [3-N-(11) C-methyl]temozolomide via in situ activation of 3-N-hydroxymethyl temozolomide and alkylation with [(11) C]methyl iodide.The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy
P2860
Q24598792-8EF04052-2970-4418-AF5B-6333B6DBC10CQ24642384-36ABEF78-92F3-4DF3-BD8F-72D531065992Q33348506-27713241-70C7-4C0A-AC8B-4AC00A88D0E3Q33394173-06D6B6AF-AE9D-47E6-8AC6-D2E880C850D3Q33396761-343B707E-1E8F-4158-A59E-9F9BA37D1B2FQ33850507-5D5EC422-EE87-4930-A442-A96267821C68Q33982978-4664E9E7-910B-4F0E-B90D-4467CF362C32Q34020065-FBB26B52-F43A-41CA-83E4-DB6024FF932DQ34051168-5E96449E-E8FC-430F-9AE3-058CFDFD17A6Q34101036-98BB4E08-985E-4BFB-B9C3-FE0D1E292CC5Q35708559-91878A29-A154-4808-AC3F-EAFB67151398Q36185580-6BDF8A0A-1973-46C1-813A-308305B00A99Q36545498-DA979405-058C-4B84-96E0-114682A517CFQ36619146-54BBFB9F-B061-478C-A44F-2D84C81AFB0BQ36940730-5EEA830C-C589-40C7-866D-E8411990EFF0Q36972613-3E24ABE3-6952-4383-9F55-96E718D8CA11Q37316983-C94F28D1-03E0-4DF3-B885-C15F655FAECCQ37450733-4FFB48CC-FA01-4FF0-800F-3056500080E6Q37621597-27A4A752-628D-4E44-9ACA-0C943293E35BQ37724340-05EC7936-A2D1-455B-9766-7FAB66ABAA76Q37789267-16A3358E-E4F8-4A64-9B71-2BD342E86442Q38010032-BE8815E1-5F85-4E98-94C4-26080E97E860Q38096437-10041879-4DAF-4871-9737-577363A7044CQ38245172-1DFB28B3-B9B6-4A67-8B0D-E6CFFE38D147Q38708463-7530F292-A4E8-424A-ADF2-D9FAC260F0AAQ39747657-AD1CE0C9-462E-41EC-BC73-B00060D18BF1Q42720641-E77838B7-C9C5-495C-BE41-01E59DC84D38Q43031053-52D8E2D0-A5C9-4AD3-B61D-DA947327FF63Q43204490-36D8CA9A-7F8D-4253-B6D1-6110BC9428FCQ45772873-286F7F6D-E534-42FA-9723-2D4CEE810129Q48592886-2B1988D8-598A-4618-B836-594764DF5C98Q50753792-691E76B2-7442-4800-94E2-ABE483C31505Q55460168-F08335E9-9607-4CF8-8DB0-76AF7AD53624Q58539482-151B4AF9-C1A8-4E12-A8A4-F70D777CA9EE
P2860
Temozolomide for the treatment of metastatic melanoma: a systematic review.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@ast
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@en
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@nl
type
label
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@ast
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@en
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@nl
prefLabel
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@ast
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@en
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@nl
P2093
P1433
P1476
Temozolomide for the treatment of metastatic melanoma: a systematic review.
@en
P2093
Manya Charette
Shailendra Verma
Teresa Petrella
P304
P356
10.1634/THEONCOLOGIST.12-9-1114
P577
2007-09-01T00:00:00Z